Clinical Trials Cultivation DEA Dispensary 
The Cannigma
JUNE 14, 2021
The federally sanctioned cannabis did not reflect the products available in dispensaries around the country, researchers complain, limiting the scope of research and pushing much of it overseas. The BRC is among the dozens of organizations that have received preliminary approval from the DEA to cultivate cannabis.
Cannabis Law Report
NOVEMBER 4, 2021
Drug Enforcement Agency (DEA) to cultivate marijuana for research purposes. The DEA dragged their feet on this plan for years, so lawsuits were filed. Use the plants for their own studies and/or FDA clinical trials. SRI received one of those licenses. And that’s not all.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
AUGUST 16, 2021
and industry-leading Cannabis Business Times, Cannabis Dispensary, and Hemp Grower magazines, announces today President of Scottsdale Research Institute (SRI) Sue Sisley, MD, as the keynote speaker on Day 2 of its annual event, to take place Aug. 24-26, 2021, at Paris Las Vegas Hotel & Casino. 25 from 11 a.m. – 24-26, 2021.
CannaMD
AUGUST 8, 2020
Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. This new bill allows broad hemp cultivation.
Cannabis Law Report
APRIL 1, 2019
It aims to turn the plants’ chemical compounds into 2,500 5-milliliter bottles – the size of a teaspoon – of cannabis oil and sublingual drops for clinical trials among volunteer patients as early as July. It remains to be seen whether the Drug Enforcement Authority, or DEA, will designate cannabis zones for these farmers.
SpeedWeed
MARCH 5, 2021
One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.
Cannabis Law Report
JUNE 4, 2021
It is quite popular and will bring more consumers, especially if a state were to regulate it so that Delta-8 would ONLY be available in dispensaries. With Delta 9, there are greater adverse effect risks and these should be explained at dispensaries that will carry and sell such products.
Expert insights. Personalized for you.
133 
Let's personalize your content